CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Orbus Pharma Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Orbus Pharma Inc.
20 Konrad Crescent
Phone: (905) 943-9444p:905 943-9444 Markham, ON  L3R 8T4  Canada Ticker: ORB ORB
This company is no longer actively traded on any major stock exchange.
Business Summary
Orbus Pharma Inc. (Orbus) is a generic drug development and manufacturing company. The Company’s product portfolio includes Metoprolol Succinate XR, Cefuroxime Axetil, Amitriptyline, Oxcarbazepine and Fluvastatin XR. Metoprolol Succinate is used alone or in combination with other medications to treat high blood pressure. This product is developed in Germany and Europe. Cefuroxime axetil is used to treat certain infections caused by bacteria, such as bronchitis, gonorrhoea, Lyme disease, and infections of the ears, throat, sinuses, urinary tract, and skin. Amitriptyline is used to treat symptoms of depression. Oxcarbazepine is used alone or in combination with other medications to treat certain types of seizures in the treatment of epilepsy. Fluvastatin XR works by slowing the production of cholesterol in the body. The Company has its manufacturing and research and development facility in Markham, Ontario and an antibiotic manufacturing facility in Cambridge, Ontario.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/200912/31/2008Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Jeffrey J.McCaig 57 9/15/2009 12/1/1989
Interim President and Chief Executive Officer, Chief Financial Officer Gregory W.Muir 9/15/2009 2/12/2007
Independent Director Franklin T.Bailey 5/30/2002 5/30/2002
3 additional Officers and Directors records available in full report.

Business Names
Business Name
OBSP
ORB
Orbus Pharma Inc
Orbus Pharma Inc.

General Information
Number of Employees: 32 (As of 12/31/2006)
Outstanding Shares: 60,943,000 (As of 6/30/2009)
Shareholders: 7,445
Stock Exchange: TSE
Fax Number: (905) 943-9878


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023